FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2282680145> ?p ?o ?g. }

• W2282680145 endingPage "490" @default.
• W2282680145 startingPage "484" @default.
• W2282680145 abstract "Thirty-one previously untreated patients with Ewing's sarcoma were treated with an intensive chemotherapy program of vincristine, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cyclosphosphamide (VADRIAC) in combination with radiation therapy to the primary site (greater than 50 Gy) and bone metastases (45 to 50 Gy). An intensified regimen with one further cycle of chemotherapy (VADRIAC), total body irradiation (TBI), and autologous bone marrow transplantation was given to patients with primary tumors of the pelvis, humerus, femur, and chest wall without metastases and to all patients with metastases at diagnosis. Patients with primary tumors of the distal extremity and other sites without metastases at diagnosis were treated on a less intensive chemotherapy regimen of VADRIAC without the intensification. Therapy was completed within 6 to 7 months in all patients. Thirteen patients had metastatic disease at diagnosis; only two of these had the lung as the sole site of metastatic disease. Eighteen patients had no evidence of metastatic disease at diagnosis: ten of these patients had tumors that arose in central axis and proximal extremity sites, and eight had tumors that arose in distal extremity and other sites. Thirty of the 31 patients achieved a complete remission, although two patients underwent amputation: one before chemotherapy and radiation and one after chemotherapy and radiation because of persistent local disease. Seventeen remain in their first complete remission at a median time on study of 30 months and a median time after completion of therapy of 24 months. Fourteen patients have relapsed (13) or progressed (1): ten in metastatic sites and four in the primary site. One patient had persistent local disease after radiation requiring amputation. Nine of the 13 patients with metastatic disease at diagnosis have relapsed compared with five of the 18 patients without metastatic disease. For the entire group, the actuarial survival is 78% (65% to 87%) at 30 months, and the actuarial disease-free survival is 58% (46% to 69%) at 30 months." @default.
• W2282680145 created "2016-06-24" @default.
• W2282680145 creator A5002810674 @default.
• W2282680145 creator A5008565383 @default.
• W2282680145 creator A5020544186 @default.
• W2282680145 creator A5033936594 @default.
• W2282680145 creator A5060374714 @default.
• W2282680145 creator A5071660818 @default.
• W2282680145 creator A5074670436 @default.
• W2282680145 creator A5077346169 @default.
• W2282680145 creator A5089798708 @default.
• W2282680145 creator A5091445831 @default.
• W2282680145 date "1988-03-01" @default.
• W2282680145 modified "2023-09-27" @default.
• W2282680145 title "Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance." @default.
• W2282680145 cites W1953430364 @default.
• W2282680145 cites W1968699015 @default.
• W2282680145 cites W1979300931 @default.
• W2282680145 cites W1980567569 @default.
• W2282680145 cites W1989412761 @default.
• W2282680145 cites W2005451489 @default.
• W2282680145 cites W2015491325 @default.
• W2282680145 cites W2028376961 @default.
• W2282680145 cites W2041319631 @default.
• W2282680145 cites W2051964401 @default.
• W2282680145 cites W2056066077 @default.
• W2282680145 cites W2061321265 @default.
• W2282680145 cites W2087090183 @default.
• W2282680145 cites W2139984188 @default.
• W2282680145 cites W2180449943 @default.
• W2282680145 cites W2224494804 @default.
• W2282680145 cites W2245710266 @default.
• W2282680145 cites W2396254309 @default.
• W2282680145 cites W2405874137 @default.
• W2282680145 cites W2408155952 @default.
• W2282680145 cites W2410222087 @default.
• W2282680145 doi "https://doi.org/10.1200/jco.1988.6.3.484" @default.
• W2282680145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3280743" @default.
• W2282680145 hasPublicationYear "1988" @default.
• W2282680145 type Work @default.
• W2282680145 sameAs 2282680145 @default.
• W2282680145 citedByCount "79" @default.
• W2282680145 countsByYear W22826801452016 @default.
• W2282680145 countsByYear W22826801452017 @default.
• W2282680145 countsByYear W22826801452020 @default.
• W2282680145 countsByYear W22826801452023 @default.
• W2282680145 crossrefType "journal-article" @default.
• W2282680145 hasAuthorship W2282680145A5002810674 @default.
• W2282680145 hasAuthorship W2282680145A5008565383 @default.
• W2282680145 hasAuthorship W2282680145A5020544186 @default.
• W2282680145 hasAuthorship W2282680145A5033936594 @default.
• W2282680145 hasAuthorship W2282680145A5060374714 @default.
• W2282680145 hasAuthorship W2282680145A5071660818 @default.
• W2282680145 hasAuthorship W2282680145A5074670436 @default.
• W2282680145 hasAuthorship W2282680145A5077346169 @default.
• W2282680145 hasAuthorship W2282680145A5089798708 @default.
• W2282680145 hasAuthorship W2282680145A5091445831 @default.
• W2282680145 hasConcept C126838900 @default.
• W2282680145 hasConcept C141071460 @default.
• W2282680145 hasConcept C142724271 @default.
• W2282680145 hasConcept C2776204877 @default.
• W2282680145 hasConcept C2776694085 @default.
• W2282680145 hasConcept C2776755627 @default.
• W2282680145 hasConcept C2777586341 @default.
• W2282680145 hasConcept C2778256501 @default.
• W2282680145 hasConcept C2779429289 @default.
• W2282680145 hasConcept C2781413609 @default.
• W2282680145 hasConcept C509974204 @default.
• W2282680145 hasConcept C71924100 @default.
• W2282680145 hasConceptScore W2282680145C126838900 @default.
• W2282680145 hasConceptScore W2282680145C141071460 @default.
• W2282680145 hasConceptScore W2282680145C142724271 @default.
• W2282680145 hasConceptScore W2282680145C2776204877 @default.
• W2282680145 hasConceptScore W2282680145C2776694085 @default.
• W2282680145 hasConceptScore W2282680145C2776755627 @default.
• W2282680145 hasConceptScore W2282680145C2777586341 @default.
• W2282680145 hasConceptScore W2282680145C2778256501 @default.
• W2282680145 hasConceptScore W2282680145C2779429289 @default.
• W2282680145 hasConceptScore W2282680145C2781413609 @default.
• W2282680145 hasConceptScore W2282680145C509974204 @default.
• W2282680145 hasConceptScore W2282680145C71924100 @default.
• W2282680145 hasIssue "3" @default.
• W2282680145 hasLocation W22826801451 @default.
• W2282680145 hasLocation W22826801452 @default.
• W2282680145 hasOpenAccess W2282680145 @default.
• W2282680145 hasPrimaryLocation W22826801451 @default.
• W2282680145 hasRelatedWork W1952212414 @default.
• W2282680145 hasRelatedWork W1973224953 @default.
• W2282680145 hasRelatedWork W1997722571 @default.
• W2282680145 hasRelatedWork W2036082666 @default.
• W2282680145 hasRelatedWork W2059330875 @default.
• W2282680145 hasRelatedWork W2121694206 @default.
• W2282680145 hasRelatedWork W2163553551 @default.
• W2282680145 hasRelatedWork W2230522317 @default.
• W2282680145 hasRelatedWork W2403331838 @default.
• W2282680145 hasRelatedWork W2415511625 @default.
• W2282680145 hasVolume "6" @default.
• W2282680145 isParatext "false" @default.

• next